Action SNBP PANBELA THERAPEUTICS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Panbela Therapeutics, Inc.

Actions

SNBP

US69833W4042

Marché Fermé - OTC Markets
Autres places de cotation
 21:57:48 28/06/2024 		Varia. 5j. Varia. 1 janv.
0,4 USD +11,11% Graphique intraday de Panbela Therapeutics, Inc. +5,26% -97,81%
24/06 Panbela Therapeutics annonce la troisième évaluation indépendante de l'innocuité de l'essai clinique de phase 3 ASPIRE Le DSMB recommande la poursuite de l'essai sans modification CI
10/06 Panbela Therapeutics, Inc. annonce une présentation orale à la Digestive Disease Week (DDW) CI

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification
GL
Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification
AQ
Panbela Announces Oral Presentation at Digestive Disease Week (DDW)
GL
Panbela Announces Oral Presentation at Digestive Disease Week (DDW)
AQ
Panbela Provides Business Update and Reports Q1 2024 Financial Results
AQ
Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac
GL
Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024
GL
Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week
GL
Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025
GL
Panbela Announces Poster Presentation at American Association for Cancer Research
AQ
Panbela Announces Poster Presentation at American Association for Cancer Research
GL
Panbela Announces Transfer to OTCQB Market
GL
Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results
AQ
Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024
GL
Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements
GL
Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements
AQ
Panbela Announces Closing of Approximately $9.0 Million Public Offering
GL
Panbela Announces Closing of Approximately $9.0 Million Public Offering
AQ
Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)
GL
Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)
AQ
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action SNBP
  4. Actualités Panbela Therapeutics, Inc.
  5. Communiqués